MediMabBio is pleased to announce that it has been selected as a resident company for the Boston Connect & Development Incubation Office program organized by the Korea Health Industry Development Institute (KHIDI). The program supports the global expansion of Korean pharmaceutical and biotechnology companies by providing access to the U.S. biotech ecosystem.
Through this program, MediMabBio has established its presence at the Cambridge Innovation Center (CIC) in Boston’s Kendall Square, one of the world’s leading biotechnology and innovation hubs.
This new presence in Boston will further strengthen MediMabBio’s clinical development capabilities in the United States and expand opportunities to engage with global pharmaceutical companies, investors, and research institutions. The company plans to leverage its Boston base to accelerate strategic partnerships and licensing opportunities for its pipeline of innovative antibody and cytokine-based therapeutics.
MediMabBio remains committed to advancing novel therapies for cancer and autoimmune diseases while strengthening its global development and business development activities.